A mutation in the ZNF687 gene that is responsible for the severe form of Paget’s disease of bone causes severely altered bone remodeling and promotes hepatocellular carcinoma onset in a knock-in mouse model

Abstract

Paget’s disease (PDB) is a late-onset bone remodeling disorder with a broad spectrum of symptoms and complications. One of the most aggressive forms is caused by the P937R mutation in the ZNF687 gene. Although the genetic involvement of ZNF687 in PDB has been extensively studied, the molecular mechanisms underlying this association remain unclear. Here, we describe the first Zfp687 knock-in mouse model and demonstrate that the mutation recapitulates the PDB phenotype, resulting in severely altered bone remodeling. Through microcomputed tomography analysis, we observed that 8-month-old mutant mice showed a mainly osteolytic phase, with a significant decrease in the trabecular bone volume affecting the femurs and the vertebrae. Conversely, osteoblast activity was deregulated, producing disorganized bone. Notably, this phenotype became pervasive in 16-month-old mice, where osteoblast function overtook bone resorption, as highlighted by the presence of woven bone in histological analyses, consistent with the PDB phenotype. Furthermore, we detected osteophytes and intervertebral disc degeneration, outlining for the first time the link between osteoarthritis and PDB in a PDB mouse model. RNA sequencing of wild-type and Zfp687 knockout RAW264.7 cells identified a set of genes involved in osteoclastogenesis potentially regulated by Zfp687, e.g., Tspan7, Cpe, Vegfc, and Ggt1, confirming its role in this process. Strikingly, in this mouse model, the mutation was also associated with a high penetrance of hepatocellular carcinomas. Thus, this study established an essential role of Zfp687 in the regulation of bone remodeling, offering the potential to therapeutically treat PDB, and underlines the oncogenic potential of ZNF687.

References

[1] Cundy T. Paget’s disease of bone. Metabolism., 2018, 80: 5-14

[2] Ralston SH. Paget’s disease of bone. N. Engl. J. Med., 2013, 368: 644-650

[3] Ralston SH et al. Diagnosis and management of Paget’s disease of bone in adults: a clinical guideline. J. Bone Miner. Res., 2019, 34: 579-604

[4] Makaram N, Woods L, Beattie N, Roberts SB, Macpherson GJ. Long-term outcomes following total hip and total knee arthroplasty in patients with Paget’s disease of bone (PDB) - a national study. Surgeon, 2020, 18: 335-343

[5] Roelofs AJ et al. Identification of the skeletal progenitor cells forming osteophytes in osteoarthritis. Ann. Rheum. Dis., 2020, 79: 1625-1634

[6] van der Kraan PM, van den Berg WB. Osteophytes: relevance and biology. Osteoarthr. Cartil., 2007, 15: 237-244

[7] Altman RD, Collins B. Musculoskeletal manifestations of Paget’s disease of bone. Arthritis Rheum, 1980, 23: 1121-1127

[8] Russo S, Scotto di Carlo F, Gianfrancesco F. The osteoclast traces the route to bone tumors and metastases. Front. Cell Dev. Biol., 2022, 10: 886305

[9] Deyrup AT et al. Sarcomas arising in Paget disease of bone: a clinicopathologic analysis of 70 cases. Arch. Pathol. Lab. Med., 2007, 131: 942-946

[10] Gianfrancesco F et al. Giant cell tumor occurring in familial Paget’s disease of bone: report of clinical characteristics and linkage analysis of a large pedigree. J. Bone Miner. Res., 2013, 28: 341-350

[11] Scotto di Carlo F, Whyte MP, Gianfrancesco F. The two faces of giant cell tumor of bone. Cancer Lett., 2020, 489: 1-8

[12] Hocking LJ et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget’s disease. Hum. Mol. Genet., 2002, 11: 2735-2739

[13] Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in paget disease of bone. Am. J. Hum. Genet., 2002, 70: 1582-1588

[14] Divisato G et al. ZNF687 mutations in severe paget disease of bone associated with giant cell tumor. Am. J. Hum. Genet., 2016, 98: 275-286

[15] Scotto di Carlo F, Pazzaglia L, Esposito T, Gianfrancesco F. The loss of profilin 1 causes early onset Paget’s disease of bone. J. Bone Miner. Res., 2020, 35: 1387-1398

[16] Rea SL, Walsh JP, Layfield R, Ratajczak T, Xu Jiake J. New insights into the role of sequestosome 1/p62 mutant proteins in the pathogenesis of paget’s disease of bone. Endocr. Rev., 2013, 34: 501-524

[17] Hiruma Y et al. A SQSTM1/p62 mutation linked to Paget’s disease increases the osteoclastogenic potential of the bone microenvironment. Hum. Mol. Genet., 2008, 17: 3708-3719

[18] Daroszewska A et al. A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget’s disease-like disorder in mice. Hum. Mol. Genet, 2011, 20: 2734-2744

[19] Daroszewska A et al. Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62 P394L mouse model of Paget’s disease. DMM Dis. Model. Mech., 2018, 11: 1-12

[20] Divisato G, Scotto di Carlo F, Petrillo N, Esposito T, Gianfrancesco F. ZNF687 mutations are frequently found in pagetic patients from South Italy: implication in the pathogenesis of Paget’s disease of bone. Clin. Genet., 2018, 93: 1240-1244

[21] Ambrosi TH et al. Adipocyte accumulation in the bone marrow during obesity and aging impairs stem cell-based hematopoietic and bone regeneration. Cell Stem Cell, 2017, 20: 771-784.e6

[22] Tencerova M et al. High-fat diet-induced obesity promotes expansion of bone marrow adipose tissue and impairs skeletal stem cell functions in mice. J. Bone Miner. Res., 2018, 33: 1154-1165

[23] Woods GN et al. Greater bone marrow adiposity predicts bone loss in older women. J. Bone Miner. Res., 2020, 35: 326-332

[24] Fan Y et al. Parathyroid hormone directs bone marrow mesenchymal cell fate. Cell Metab., 2017, 25: 661-672

[25] Dutta S, Sengupta P. Men and mice: Relating their ages. Life Sci., 2016, 152: 244-248

[26] Fang H, Beier F. Mouse models of osteoarthritis: modelling risk factors and assessing outcomes. Nat. Rev. Rheumatol., 2014, 10: 413-421

[27] Palmieri M et al. Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum. Mol. Genet., 2011, 20: 3852-3866

[28] Kwon JO et al. Tetraspanin 7 regulates sealing zone formation and the bone-resorbing activity of osteoclasts. Biochem. Biophys. Res. Commun., 2016, 477: 1078-1084

[29] Kim M et al. Tetraspanin 7 regulates osteoclast function through association with the RANK/αvβ3 integrin complex. J. Cell. Physiol., 2022, 237: 846-855

[30] Kim HJ, Hong JM, Yoon HJ, Yoon YR, Kim SY. Carboxypeptidase E is a novel modulator of RANKL-induced osteoclast differentiation. Mol. Cells, 2014, 37: 685-690

[31] Zhang Q et al. VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism. J. Biol. Chem., 2008, 283: 13491-13499

[32] Hominick D et al. VEGF-C promotes the development of lymphatics in bone and bone loss. Elife, 2018, 7: e34323

[33] Niida S et al. γ-Glutamyltranspeptidase stimulates receptor activator of nuclear factor-κB ligand expression independent of its enzymatic activity and serves as a pathological bone-resorbing factor. J. Biol. Chem., 2004, 279: 5752-5756

[34] Hiramatsu K et al. Overexpression of gamma-glutamyltransferase in transgenic mice accelerates bone resorption and causes osteoporosis. Endocrinology, 2007, 148: 2708-2715

[35] Scotto di Carlo, F. et al. ZNF687 mutations in an extended cohort of neoplastic transformations in Paget’s disease of bone: implication for clinical pathology. J. Bone Miner. Res. 35, 1974–1980 (2020).

[36] Sánchez-Martın P, Komatsu M. p62/SQSTM1 - steering the cell through health and disease. J. Cell Sci., 2018, 131: jcs222836

[37] Kurihara N et al. Expression of measles virus nucleocapsid protein in osteoclasts induces Paget’s disease-like bone lesions in mice. J. Bone Min. Res., 2006, 21: 446-455

[38] Kurihara N et al. Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62P392L mutation to paget’s disease. Cell Metab., 2011, 13: 23-34

[39] Teramachi J et al. Measles virus nucleocapsid protein increases osteoblast differentiation in Paget’s disease. J. Clin. Invest., 2016, 126: 1012-1022

[40] Wallace RGH, Barr RJ, Osterberg PH, Mollan RAB. Familial expansile osteolysis. Clin. Orthop. Relat. Res., 1989, 248: 265-277

[41] Yu W et al. Bone marrow adipogenic lineage precursors promote osteoclastogenesis in bone remodeling and pathologic bone loss. J. Clin. Invest., 2021, 131: e140214

[42] Hu Y et al. RANKL from bone marrow adipose lineage cells promotes osteoclast formation and bone loss. EMBO Rep., 2021, 22: e52481

[43] Bianco P et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat. Med., 2013, 19: 35-42

[44] Lehman HL, Stairs DB. Single and multiple gene manipulations in mouse models of human cancer. Cancer Growth Metastasis, 2015, 8s1: CGM.S21217

[45] Zhang T et al. Overexpression of zinc finger protein 687 enhances tumorigenic capability and promotes recurrence of hepatocellular carcinoma. Oncogenesis, 2017, 6: e363

[46] van’t Hof RJ, Rose L, Bassonga E, Daroszewska A. Open source software for semi-automated histomorphometry of bone resorption and formation parameters. Bone, 2017, 99: 69-79

[47] Nagtegaal ID et al. The 2019 WHO classification of tumours of the digestive system. Histopathology, 2020, 76: 182-188

[48] Edmondson, H. A. & Steiner, P. E. Primary carcinoma of the liver a study of 100 cases among 48,900 Necropsies. Cancer 7, 462–503 (1954).

[49] Maridas DE, Rendina-Ruedy E, Le PT, Rosen CJ. Isolation, culture, and differentiation of bone marrow stromal cells and osteoclast progenitors from mice. J. Vis. Exp., 2018, 131: e56750

[50] Dobin A, Gingeras TR. Mapping RNA-seq reads with STAR. Curr. Protoc. Bioinforma., 2015, 51: 11.14.1-11.14.19

[51] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 2014, 15: 550

[52] Zhu A, Ibrahim JG, Love MI. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics, 2019, 35: 2084-2092

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)(ID 25110)

European Calcified Tissue Society (ECTS)